摘要
目的：探讨肝复乐防治免疫性肝纤维化的效果及机制。方法：猪血清腹腔内注射复制SD大鼠肝纤维化模型,肝复乐混悬液经口灌胃干预。行病理及生化监测。结果：(1)12周,肝复乐组与模型组比较,血清ALT、β-GT降低、ALB升高,肝组织MDA、HYP降低,GSH上升。肝贮脂细胞数目减少,纤维化分级减轻。(2)肝复乐组16周与12周比较,除贮脂细胞数目无明显变化外,余改变同以上指标。结论：肝复乐可参与抑制贮脂细胞激活,促进细胞外基质降解等多个环节而减轻肝纤维化,但不能阻断肝纤维化发展。
Objective： To investigate the efficacy of the treatment and prevention of the chinese patent drug ganfule and its mechanisms involved in rats with liver fibrosis induced by porcine serum. Methods： SD rats were dealt with porcine serum via the intraperitoneal injection as well as applied the ganfule suspension via the intragastric administration. The assessment was done by way of pathology and biochemistry. Results： （1） Compared with the model group in 12 weeks, ganfule group could be seen with a decrease of ALT, γ-GT and an increase of ALB in sere as a decrease of MDA, HYP and an increase of GSH in liver tissue. Moreover, the number of fat-storing cell and the grade of liver fibrosis in ganfule group appeared a decrease in contrast with that in the model group. （2） A comparison of ganfule in 16 weeks with it in 12 weeks showed that chan ges were the same as the above items except no significant change in the number of fat-storing cell. Conclusion： Although ganrule play a rule in inhibiting the activation of fat-storing cell and promoting the degradation of the extracellular matrix, it could not thoroughly interrupt the development of liver fibrosis.
出处
《国际消化病杂志》
CAS
2006年第6期428-430,共3页
International Journal of Digestive Diseases
关键词
肝复乐
肝纤维化
贮脂细胞
Ganfule
Hepatic fibrosis, Fat-storing cell
